WE NEED YOUR HELP!
Please donate to keep ReaderRant online to serve political discussion and its members. (Blue Ridge Photography pays the bills for RR).
adjusted for severity of illness, the lack of advantage from HCQ remains
That would be true if their "adjustment for severity of illness" was for a linear illness progression. But it looks like serious Covid-19 progression is almost two different illnesses. During the earlier virus replication phase, antivirals might have an effect. During the later predominately inflammation phase, antivirals have little effect. The amount of virus may actually be going down anyway, because of the immune system response. This phase is essentially an acute autoimmune disease. The important pathology is the attack on the endothelium and the resulting VWF clotting and thrombosis. That's why EVMS only uses HCN in the early phases, and then treats the inflammation phase with prednisolone and heparin and no more HCN or remdesivir.
So we have no new data. All we know is that it looks like HCN is useless in the latter phases.
